Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials

Introduction The efficacy and safety of the once-daily topical ophthalmic solutions, alcaftadine 0.25% and olopatadine 0.2%, in preventing ocular itching associated with allergic conjunctivitis were evaluated. Methods Pooled analysis was conducted of two double-masked, multicenter, active- and place...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2014-10, Vol.31 (10), p.1059-1071
Main Authors: McLaurin, Eugene B., Marsico, Nicholas P., Ackerman, Stacey L., Ciolino, Joseph B., Williams, Julia M., Villanueva, Linda, Hollander, David A.
Format: Article
Language:English
Subjects:
Adult
Allergens
Anti-Allergic Agents - administration & dosage
Anti-Allergic Agents - adverse effects
Benzazepines - administration & dosage
Benzazepines - adverse effects
Biological and medical sciences
Cardiology
Conjunctivitis, Allergic - complications
Conjunctivitis, Allergic - diagnosis
Conjunctivitis, Allergic - drug therapy
Double-Blind Method
Drug Monitoring
Endocrinology
Female
Humans
Imidazoles - administration & dosage
Imidazoles - adverse effects
Internal Medicine
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Olopatadine Hydrochloride - administration & dosage
Olopatadine Hydrochloride - adverse effects
Oncology
Ophthalmic Solutions
Original Research
Patient Outcome Assessment
Pharmacology. Drug treatments
Pharmacology/Toxicology
Pruritus - etiology
Pruritus - prevention & control
Rheumatology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The efficacy and safety of the once-daily topical ophthalmic solutions, alcaftadine 0.25% and olopatadine 0.2%, in preventing ocular itching associated with allergic conjunctivitis were evaluated. Methods Pooled analysis was conducted of two double-masked, multicenter, active- and placebo-controlled studies using the conjunctival allergen challenge (CAC) model of allergic conjunctivitis. Subjects were randomized 1:1:1 to receive alcaftadine 0.25%, olopatadine 0.2%, or placebo. The primary efficacy measure was subject-evaluated mean ocular itching at 3 min post-CAC and 16 h after treatment instillation. Secondary measures included ocular itching at 5 and 7 min post-CAC. Ocular itch was determined over all time points measured (3, 5, and 7 min) post-CAC and the proportion of subjects with minimal itch (itch score
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-014-0155-3